Analysts Offer Insights on Healthcare Companies: GenMark (NASDAQ: GNMK) and Boston Scientific Corp (NYSE: BSX)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GenMark (NASDAQ: GNMK) and Boston Scientific Corp (NYSE: BSX).

GenMark (NASDAQ: GNMK)

BTIG analyst Karen Koski reiterated a Buy rating on GenMark (NASDAQ: GNMK) yesterday and set a price target of $17. The company’s shares opened today at $13.32, close to its 52-week high of $13.67.

According to TipRanks.com, Koski is a 4-star analyst with an average return of 12.1% and a 64.0% success rate. Koski covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Orasure Technologies, and Foundation Medicine.

Currently, the analyst consensus on GenMark is Strong Buy and the average price target is $15.88, representing a 19.2% upside.

In a report issued on May 2, Canaccord Genuity also reiterated a Buy rating on the stock with a $17 price target.
Boston Scientific Corp (NYSE: BSX)

In a report released yesterday, Sean Lavin from BTIG reiterated a Hold rating on Boston Scientific Corp (NYSE: BSX). The company’s shares opened today at $26.48, close to its 52-week high of $26.76.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 11.4% and a 58.5% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Obalon Therapeutics Inc.

Currently, the analyst consensus on Boston Scientific Corp is Moderate Buy and the average price target is $28.63, representing an 8.1% upside.

In a report released yesterday, Goldman Sachs also initiated coverage with a Hold rating on the stock with a $28 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.